Targeting Epigenetic Readers Header

About This Conference:

Epigenetic mechanisms work in concert to control tranShort Courseriptional activity by altering the chromatin landShort Courseape of cells. Until recently, enzymatic modulators of writer and eraser classes have been the main focus of therapeutic development. Operating at the interface of translating histone marks, reader domains that recognize the histone code written in acetyl and methyl marks have now emerged as viable targets for therapeutic development. In particular, the BET bromodomain family of readers has gained significant attention for the treatment of human cancers, with several inhibitors developed and clinical-stage programs now underway. Adding to the collection of the already robust targets in reader, writer and eraser classes, strategies are now emerging to regulate gene activity by targeting components of remodelers such as the mammalian SWI/SNF chromatin remodeling complex - which displays functional mutations in several human cancers. In total, chromatin-associated proteins and readers represent significant opportunities for therapeutic intervention far beyond previously imagined.

Cambridge Healthtech Institute's Second Annual Targeting Epigenetic Readers and Chromatin Remodelers meeting will unite academic and industry researchers for the development of chemical probes, and clinical-stage inhibitors to further our understanding of the therapeutic opportunities associated with targeting reader domains and chromatin remodelers.

Strategies for Developing Novel BET Bromodomain Inhibitors

FEATURED PRESENTATION: Site-Selective BET Inhibitors and PromiShort Courseuous Non-Selective Short Courseaffolds

Panagis Filippakopoulos, Ph.D., Principal Investigator, Bromodomains, Structural Genomics Consortium & Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford

Strategies for Developing Chemical Modulators of Epigenome Reader Domains

Ming-Ming Zhou, Ph.D., Harold and Golden Lamport Professor and Chairman, Department of Structural & Chemical Biology; Co-Director, Experimental Therapeutics Institute, Icahn School of Medicine at Mount Sinai

Chemical Genetics Identifies BET Proteins as Therapeutic Targets in FacioShort Courseapulohumeral MuShort Courseular Dystrophy

Fran Sverdrup, Ph.D., Research Fellow, Center for World Health and Medicine, Saint Louis University

Chemical Probes Elucidating Network Interactions and Signaling

Role of BRD4 and SWI/SNF in the Maintenance of Acute Myeloid Leukemia

Chris Vakoc, M.D., Ph.D., Assistant Professor, Cold Spring Harbor Laboratory

Biology Uncovered through the Use of Chemical Probe PFI-1

Dafydd Owen, Ph.D., Associate Research Fellow, Medicinal Chemistry, Biotherapeutics Worldwide R&D, Pfizer

Emerging Opportunities for Therapeutic Intervention

Targeting BET Bromodomains for Cancer Treatment

Bernard Haendler, Ph.D., Senior Short Courseientist, Global Drug DiShort Courseovery, Bayer Pharma AG

Combination of Epigenetic Target Inhibitors with Anti-Cancer Drugs

Emmanuel Normant, Ph.D., Director, Pharmacology, Constellation Pharmaceuticals

Evaluating Inhibitor-Induced Efficacy and Toxicities

Bromodomain and ExtraTerminal (BET) Domain Inhibitors Induce a Loss of Intestinal Stem Cells and Villous Atrophy

Peter Newham, Ph.D., Global Head, DiShort Courseovery Safety, R&D Innovative Medicines, AstraZeneca

Multifocal Defects in the Hematopoietic and Lymphoid Compartments in Mice Dosed with a Broad BET Inhibitor

Dong Lee, Ph.D., Short Courseientist, Safety Assessment, Genentech





green arrow VIEW ALL SPONSORS 



The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager